文献速递冠心病肺血管病与心包/心肌炎血脂与心血管预防

COMPASS试验:低剂量利伐沙班联合阿司匹林对比单用阿司匹林在慢性血管疾病患者中的净临床获益

The COMPASS Trial: Net Clinical Benefit of Low-Dose Rivaroxaban Plus Aspirin as Compared With Aspirin in Patients With Chronic Vascular Disease.
PubMed 文献 · Circulation · 2020-05-21

COMPASS试验的预设分析评估慢性血管疾病患者中利伐沙班2.5mg每日两次联合阿司匹林100mg对比阿司匹林单药治疗的净临床获益。结果显示联合治疗组净临床获益不良结局更少(HR 0.80,95%CI 0.70-0.91,P=0.0005),主要由卒中和心血管死亡减少驱动,致死性出血仅占少数事件,高危亚组获益更明显。

要点

  • 获益主要来自卒中和心血管死亡减少,致死性出血风险未显著增加。
  • 多血管床病变、肾功能不全、心衰和/或糖尿病患者绝对风险降幅更大。

核心结论

  • 与阿司匹林单药相比,利伐沙班2.5mg每日两次联合阿司匹林减少净临床获益事件,主要通过预防卒中和心血管死亡实现。
  • 严重出血较少且临床影响较小,净临床获益在高危亚组中尤为有利。

研究设计与样本

  • COMPASS试验的预设分析,采用意向治疗人群,评估慢性血管疾病患者的净临床获益。
  • 预设净临床获益结局为心血管死亡、卒中、心肌梗死、致死性出血或症状性关键器官出血的复合终点。

主要发现

  • 联合治疗组净临床获益不良结局少于阿司匹林单药组(HR 0.80,95%CI 0.70-0.91,P=0.0005),且随治疗时间延长更有利。
  • 卒中年发生率联合组0.5% vs 单药组0.8%(HR 0.58,95%CI 0.44-0.76,P<0.0001)。
  • 心血管死亡年发生率联合组0.9% vs 单药组1.2%(HR 0.78,95%CI 0.64-0.96,P=0.02)。
  • 致死性出血年发生率联合组0.09% vs 单药组0.06%(HR 1.49,95%CI 0.67-3.33,P=0.32)。
  • 多血管床病变、肾功能不全、心衰和/或糖尿病等高危亚组净临床获益事件绝对风险降幅更大。

临床怎么用

  • 对慢性血管疾病患者,可考虑利伐沙班2.5mg每日两次联合阿司匹林100mg以降低卒中及心血管死亡风险。
  • 优先用于多血管床病变、肾功能不全、心衰和/或糖尿病等高危患者,其绝对净获益更大。
  • 联合治疗时严重出血虽不显著增加,但仍需评估出血风险。

局限性

  • 本文为预设分析,未报告亚组交互作用P值。
  • 致死性出血事件数少,置信区间宽,结论需谨慎解读。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Rivaroxaban 2.5 mg twice daily plus acetylsalicylic acid (aspirin; ASA) 100 mg reduced the risk of cardiovascular events as compared with ASA monotherapy in the COMPASS trial (Cardiovascular Outcomes for People Using Anticoagulation Strategies) but increased the risk of major bleedings. Analysis of net clinical benefit (NCB) is of key clinical relevance and represents an integrated measure of overall patient outcome. METHODS: The current prespecified analysis was performed to assess the NCB of adding rivaroxaban 2.5 mg twice daily to ASA monotherapy in patients with chronic vascular disease in the COMPASS study cohort (intention-to-treat study population), with a specific focus on high-risk subgroups. The predefined NCB outcome was the composite of cardiovascular death, stroke, myocardial infarction, fatal bleeding, or symptomatic bleeding into a critical organ. RESULTS: A lower number of NCB adverse outcomes was observed with rivaroxaban 2.5 mg twice daily plus ASA versus ASA alone (hazard ratio, 0.80 [95% CI, 0.70-0.91], P=0.0005), which became increasingly favorable with longer treatment duration. The main drivers of NCB outcomes were "efficacy" events, in particular stroke (0.5%/y versus 0.8%/y; hazard ratio, 0.58 [95% CI, 0.44-0.76], P<0.0001) and cardiovascular death (0.9%/y versus 1.2%/y; hazard ratio, 0.78 [95% CI, 0.64-0.96], P=0.02), whereas the bleeding components of the NCB, in particular fatal bleeding (0.09%/y versus 0.06%/y; hazard ratio, 1.49 [95% CI 0.67-3.33], P=0.32), only represented a minority of NCB events. In selected high-risk subgroups, including patients with polyvascular disease (≥2 vascular beds affected with atherosclerosis), impaired renal function, heart failure, and/or diabetes mellitus, a larger absolute risk reduction for experiencing a NCB event was observed. CONCLUSIONS: Compared with ASA monotherapy, the combination of rivaroxaban 2.5 mg twice daily plus ASA resulted in fewer NCB events primarily by preventing adverse efficacy events, particularly stroke and cardiovascular mortality, whereas severe bleedings were less frequent and with less clinical impact. The NCB was particularly favorable in high-risk subgroups and those with multiple risk characteristics. Registration: URL: https://www.clinicaltrials.gov; Unique identifier: NCT01776424.

来源:Circulation,查看原文。版权归原作者所有。

引用

  1. Steffel J, Eikelboom JW, Anand SS, et al. The COMPASS Trial: Net Clinical Benefit of Low-Dose Rivaroxaban Plus Aspirin as Compared With Aspirin in Patients With Chronic Vascular Disease. Circulation. 2020. PMID: 32436455. doi:10.1161/CIRCULATIONAHA.120.046048

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。